Accolade Inc. Stock News

Shares of Accolade Inc. lost nearly half their value Friday, after the personalized virtual health care services company reported a wider-than-expected fiscal fourth-quarter loss, and said it would lo

ACCD earnings call for the period ending March 31, 2022.

Accolade, Inc. (NASDAQ:NASDAQ:ACCD) Q4 2022 Earnings Conference Call April 28, 2022, 04:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu...

Accolade, Inc. (NASDAQ:ACCD ) Q4 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medic

Accolade (ACCD) delivered earnings and revenue surprises of -17.39% and 1.82%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Accolade (ACCD) delivered earnings and revenue surprises of -17.39% and 1.82%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE, April 28, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 28, 2022.

Shares of American Well Corp. plumbed record lows Thursday, dragged down by a brutally disappointing outlook from fellow online health care services provider, and market leader Teladoc Inc.

SEATTLE, April 14, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal fo

Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 0 1 0 Last 30D 0

Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st

Upgrades According to Wolfe Research, the prior rating for Cullen/Frost Bankers Inc (NYSE:CFR) was changed from Underperform to Outperform. For the fourth quarter, Cullen/Frost Bankers had an EPS of $

Accolade (NASDAQ:ACCD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1

Accolade (NASDAQ: ACCD ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 1 0 0 0 These 5 analysts have an average price target of $31.8 versus the current price of Accolade at $16.295, implying upside. Below is a summary of how these 5 analysts rated Accolade over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the … Full story available on Benzinga.com

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Globa